Combination products services market

Chapter Outlines

Chapter 2 is an executive summary of the key insights captured during our research. It offers a high-level view on the current state of the combination product service providers market and its likely evolution in the mid to long term.

Chapter 3 provides an overview of combination products, along with information on various types of combination products. Additionally, it includes information on the various challenges associated with development and testing of combination products. Further, it features a brief discussion on the growing need for outsourcing within this domain.

Chapter 4 provides a detailed review of the overall landscape of combination product service providers along with information on over 25 service providers that claim to provide development and testing services for combination products. Additionally, it features an in-depth analysis of service providers, based on several relevant parameters, such as year of establishment, company size (very small, small, mid-sized, large and very large), location of headquarters, type of combination product(s) (drug delivery device / system, device coated / impregnated with drug, and  other types of combination products), type of device(s) (autoinjectors, pen-injectors, prefilled syringes, large volume wearable injectors and other types of devices), service focus area(s) (particle testing, performance testing, and product development), type of service(s) offered (chemical characterization / testing, closure integrity testing, packaging validation, process development and validation, stability studies and other types of services), location of facility and leading players (in terms of number of services offered).

Chapter 5 features a detailed company competitiveness analysis of the combination product service providers, based on several relevant parameters, such as supplier power (based on the experience of the developer in this industry) and service portfolio strength based on several relevant parameters, such as type of combination product(s) (device coated / impregnated with drug, drug delivery device / system, and other types of combination products), type of device(s) (autoinjectors, pen-injectors, prefilled syringes, large volume wearable injectors and other types of devices), service focus area(s), (particle testing, performance testing, and product development), types of service(s) offered (chemical characterization / testing, closure integrity testing, packaging validation, process development and validation, stability studies and other types of services), and number of accreditations / certifications.

Chapter 6 provides detailed profiles of the key players (shortlisted based on a proprietary criterion) that are active in the combination product services market. Each profile provides an overview of the company, along with information on year of establishment, location of headquarters, number of employees, key executives, details on recent developments, and an informed future outlook.

Chapter 7 presents a detailed analysis of the recent expansions undertaken by various combination product service providers, based on several relevant parameters, such as year of expansion, type of expansion (capacity expansions, facility expansions and new facility additions), location of expanded facility, most active players (in terms of number of recent expansions) and geographical distribution.

Chapter 8 features an elaborate discussion on combination products, with special focus on large volume wearable injectors and  prefilled syringes. The chapter includes a detailed analysis based on specific parameters for each product category, namely [A] large volume wearable injector combination products based on their phase of development, type of device, drug compatibility, type of dosage, route of administration, method of administration, therapeutic area, storage volume / capacity, usability, technology used, mechanism of action and type of drug container and [B] prefilled syringe combination products (therapies that have approved / are being developed in combination prefilled syringes) based on type of drug molecule,  year of approval (for approved therapies), geography (for approved therapies), route of administration, therapeutic area, dose strength (for approved therapies), and other available dosage forms (for approved therapies).

Chapter 9 features a list of 90+ stakeholders that are anticipated to partner with combination product service providers in the foreseen future. The players have been shortlisted based on a detailed analysis of relevant parameters, namely pipeline strength (in terms of number of product that have been / are being developed by the player), developer strength (based on player’s experience in the domain) and product strength.

Chapter 10 presents an insightful analysis that highlights the various factors that need to be taken into consideration by combination product developers, while deciding whether to manufacture their respective products in-house or engage the services of a CMO. Further, the analysis highlights all the key parameters that must be considered by players of different company sizes (very small, small, mid-sized, and large) while taking the aforementioned decision.

Chapter 11 features a comprehensive market forecast analysis, highlighting the likely growth of the combination product services market, for the period 2022-2035. Additionally, the report features the likely distribution of the current and forecasted opportunity across types of devices (autoinjectors, prefilled syringes, large volume wearable injectors and other types of devices), service focus areas (particle testing, performance testing and product development), company size (very small, small, mid-sized, large and very large), and key geographical regions (North America, Europe, Asia, and rest of the world).

Chapter 12 is a summary of the entire report. In this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.

Chapter 13 provides the transcripts of interviews conducted with representatives from renowned organizations, which are engaged in the domain of combination product services.

Chapter 14 is an appendix, that provides tabulated data and numbers for all the figures included in the report.

Chapter 15 is an appendix that provides the list of companies and organizations that have been mentioned in the report.

Table Of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Introduction to Combination Products
3.3. Challenges Associated with Development of Combination Products
3.4. Outsourced Combination Products Operations / Services
3.5. Advantages of Outsourcing Operations for Combination Products
3.6. Key Considerations while Selecting a CDMO
3.7. Future Perspectives

4. COMBINATION PRODUCTS SERVICE PROVIDERS: MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Combination Products Service Providers: Overall Market Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Location of Headquarters
4.2.4. Analysis by Type of Combination Product
4.2.5. Analysis by Type of Device
4.2.6. Analysis by Service Focus Area(s)
4.2.7. Analysis by Type of Service(s) Offered
4.2.8. Analysis by Location of Facility
4.2.9. Leading Combination Products Service Providers: Analysis by Number ofService(s) Offered
4.2.10. 4D Bubble Representation: Analysis by Company Size, Location of Headquarters(Region), Number of Service Focus Area(s) and Number of Service(s) Offered
4.2.11. Mekko Representation: Analysis by Company Size and Number of Service Focus Area(s)

5. COMPANY COMPETITIVENESS ANALYSIS
5.1. Chapter Overview
5.2. Assumptions / Key Parameters
5.3. Methodology
5.4. Combination Products Service Providers: Company Competitiveness Analysis
5.4.1. Combination Products Service Providers based in North America
5.4.2. Combination Products Service Providers based in Europe and Asia

6. COMBINATION PRODUCTS SERVICE PROVIDERS: COMPANY PROFILES
6.1. Chapter Overview
6.2. EKG LABS
6.2.1. Company Overview
6.2.2. Recent Developments and Future Outlook

6.3. Eurofins Medical Device Testing
6.3.1. Company Overview
6.3.2. Recent Developments and Future Outlook

6.4. Exponent
6.4.1. Company Overview
6.4.2. Recent Developments and Future Outlook

6.5. Kymanox
6.5.1. Company Overview
6.5.2. Recent Developments and Future Outlook

6.6. Medical Engineering Technologies
6.6.1. Company Overview
6.6.2. Recent Developments and Future Outlook

6.7. Pace Analytical Services
6.7.1. Company Overview
6.7.2. Recent Developments and Future Outlook

6.8. Suttons Creek
6.8.1. Company Overview
6.8.2. Recent Developments and Future Outlook

6.9. West Pharmaceutical Services
6.9.1. Company Overview
6.9.2. Recent Developments and Future Outlook

6.10. Concluding Remarks: Initiatives Undertaken by Industry Players

7. RECENT EXPANSIONS
7.1. Chapter Overview
7.2. Combination Products Service Providers: List of Recent Expansions
7.2.1. Analysis by Year of Expansion
7.2.2. Analysis by Type of Expansion
7.2.3. Analysis by Location of Expanded Facility
7.2.4. Analysis by Type of Expansion (Country-wise)
7.2.5. Most Active Players: Analysis by Number of Expansions
7.2.6. Geographical Analysis

8. CASE STUDY: LARGE VOLUME WEARABLE INJECTORS AND PREFILLED SYRINGES COMBINATION PRODUCTS
8.1. Chapter Overview
8.2. Large Volume Wearable Injector Combination Products
8.2.1. Large Volume Drug Device Combination Products: Market Landscape
8.2.1.1. Analysis by Phase of Development
8.2.1.2. Analysis by Type of Device
8.2.1.3. Analysis by Drug Compatibility
8.2.1.4. Analysis by Type of Dosage
8.2.1.5. Analysis by Route of Administration
8.2.1.6. Analysis by Method of Administration
8.2.1.7. Analysis by Therapeutic Area
8.2.1.8. Analysis by Storage Volume / Capacity
8.2.1.9. Analysis by Usability
8.2.1.10. Analysis by Technology Used
8.2.1.11. Analysis by Mechanism of Action
8.2.1.12. Analysis by Type of Drug Container

8.2.2. Large Volume Drug Device Combination Products: Developer Landscape
8.2.2.1. Analysis by Year of Establishment
8.2.2.2. Analysis by Company Size
8.2.2.3. Analysis by Location of Headquarters
8.2.2.4. Most Active Players: Analysis by Number of Products Manufactured

8.3. Prefilled Syringes Combination Products
8.3.1. Prefilled Syringe Combination Products: List of Approved Drugs, 2013-2021
8.3.1.1. Analysis by Type of Drug Molecule
8.3.1.2. Analysis by Approval Year
8.3.1.3. Analysis by Geography
8.3.1.4. Analysis by Route of Administration
8.3.1.5. Analysis by Therapeutic Area
8.3.1.6. Analysis by Dosage Strength
8.3.1.7. Analysis by Other Approved Dosage Forms

8.3.2. Prefilled Syringe Combination Products: List of Clinical Stage Drugs
8.3.2.1. Analysis by Type of Drug Molecule
8.3.2.2. Analysis by Phase of Development
8.3.2.3. Analysis by Route of Administration
8.3.2.4. Analysis by Therapeutic Area

8.3.3. Prefilled Syringes Combination Products: Information on Developers
8.3.3.1. Analysis by Year of Establishment
8.3.3.2. Analysis by Company Size
8.3.3.3. Analysis by Location of Headquarters

9. LIKELY PARTNER ANALYSIS
9.1. Chapter Overview
9.2. Large Volume Wearable Injectors Combination Products
9.2.1. Scoring Criteria and Key Assumptions
9.2.2. Scope and Methodology
9.2.3. Potential Strategic Partners
9.2.3.1. Most Likely Partners
9.2.3.2. Likely Partners
9.2.3.3. Less Likely Partners
9.3. Prefilled Syringes Combination Products
9.3.1. Scoring Criteria and Key Assumptions
9.3.2. Scope and Methodology
9.3.3. Potential Strategic Partners
9.3.3.1. Most Likely Partners
9.3.3.2. Likely Partners
9.3.3.3. Less Likely Partners

10. OUTSOURCING: GO / NO-GO FRAMEWORK
10.1. Chapter Overview
10.2. Outsourcing: Go / No-Go Framework
10.3. Prefilled Syringes Combination Products Developers: Go / No-Go Framework
10.3.1. Assumptions and Key Parameters
10.3.2. Methodology
10.3.3. Results and Interpretations
10.3.3.1. Outsourcing: Go / No-Go Framework for Very Small and Small Companies
10.3.3.2. Outsourcing: Go / No-Go Framework for Mid-sized Companies
10.3.3.3. Outsourcing: Go / No-Go Framework for Large Companies

11. MARKET FORECAST
11.1. Chapter Overview
11.2. Key Assumptions and Forecast Methodology
11.3. Global Combination Products Service Providers Market, 2022-2035
11.3.1. Global Combination Products Service Providers Market: Distribution by Type of Device, 2022 and 2035
11.3.1.1. Combination Products Service Providers Market for Large Volume Wearable Injectors
11.3.1.2. Combination Products Service Providers Market for Autoinjector Combination Products
11.3.1.3. Combination Products Service Providers Market for Prefilled Syringe
11.3.1.4. Combination Products Service Providers Market for Other Types of Combination Products

11.3.2. Global Combination Products Service Providers Market: Distribution by Service Focus Area, 2022 and 2035
11.3.2.1. Combination Products Service Providers Market for Particle Testing
11.3.2.2. Combination Products Service Providers Market for Performance Testing
11.3.2.3. Combination Products Service Providers Market for Product Development

11.3.3. Global Combination Products Service Providers Market: Distribution by Company Size, 2022 and 2035
11.3.3.1. Combination Products Service Providers Market for Very Small Companies
11.3.3.2. Combination Products Service Providers Market for Small Companies
11.3.3.3. Combination Products Service Providers Market for Mid-sized Companies
11.3.3.4. Combination Products Service Providers Market for Large Companies
11.3.3.5. Combination Products Service Providers Market for Very Large Companies

11.3.4 Combination Products Service Providers Market: Distribution by Region, 2022 and 2035
11.3.4.1. Combination Products Service Providers Market in North America, 2022-2035
11.3.4.2. Combination Products Service Providers Market in Europe, 2022-2035
11.3.4.3. Combination Products Service Providers Market in Asia, 2022-2035
11.3.4.4. Combination Products Service Providers in Rest of the World, 2022-2035

12. CONCLUDING REMARKS

13. EXECUTIVE INSIGHTS

14. APPENDIX 1: TABULATED DATA

15. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 2.1 Executive Summary: Combination Products Service Providers Market Landscape
Figure 2.2 Executive Summary: Recent Expansions
Figure 2.3 Executive Summary: Case Study on Large Volume Wearable Injectors and Prefilled Syringes Combination Products
Figure 2.4 Executive Summary: Market Forecast
Figure 3.1 Types of Combination Products
Figure 3.2 Recently Approved Combination Products
Figure 3.3 Challenges Associated with Development of Combination Products
Figure 3.4 Key Outsourced Combination Product Operations / Services
Figure 4.1 Combination Products Service Providers: Distribution by Year of Establishment
Figure 4.2 Combination Products Service Providers: Distribution by Company Size
Figure 4.3 Combination Products Service Providers: Distribution by Location of Headquarters
Figure 4.4 Combination Products Service Providers: Distribution by Company Size and Location of Headquarters
Figure 4.5 Combination Products Service Providers: Distribution by Type of Combination Product
Figure 4.6 Combination Products Service Providers: Distribution by Company Size and Type of Combination Product
Figure 4.7 Combination Products Service Providers: Distribution by Type of Device
Figure 4.8 Combination Product Service Providers: Distribution by Service Focus Area(s)
Figure 4.9 Combination Product Service Providers: Distribution by Type of Service(s) Offered
Figure 4.10 Combination Product Service Providers: Distribution by Location of Facility (Region-wise)
Figure 4.11 Combination Product Service Providers: Distribution by Location of Facility (Country-wise)
Figure 4.12 Leading Combination Products Service Providers: Distribution by Number of Service(s) Offered
Figure 4.13 4D Bubble Representation: Distribution by Company Size, Location of Headquarters (Region), Number of Service Focus Area(s) and Number of Service(s) Offered
Figure 4.14 Mekko Representation: Distribution by Company Size and Service Focus Area(s)
Figure 5.1 Company Competitiveness Analysis: Players based in North America
Figure 5.2 Company Competitiveness Analysis: Players based in Europe and Asia
Figure 6.1 Company Profiles: Initiatives Undertaken by Industry Players
Figure 7.1 Recent Expansions: Cumulative Year-wise Trend, 2017-2022
Figure 7.2 Recent Expansions: Distribution by Type of Expansion
Figure 7.3 Recent Expansions: Distribution by Year of Expansion and Type of Expansion
Figure 7.4 Recent Expansions: Distribution by Location of Expanded Facility
Figure 7.5 Recent Expansions: Distribution by Type of Expansion (Country-wise)
Figure 7.6 Recent Expansions: Distribution by Location of Expanded Facility and Type of Expansion (Country-wise)
Figure 7.7 Most Active Players: Distribution by Number of Expansions
Figure 9.1 Large Volume Drug Device Combination Products: Distribution by Phase of Development
Figure 9.2 Large Volume Drug Device Combination Products: Distribution by Type of Device
Figure 9.3 Large Volume Drug Device Combination Products: Distribution by Mechanism of Action
Figure 9.4 Large Volume Drug Device Combination Products: Distribution by Type of Technology Used
Figure 9.5 Large Volume Drug Device Combination Products: Distribution by Route of Administration
Figure 9.6 Large Volume Drug Device Combination Products: Distribution by Method of Administration
Figure 9.7 Large Volume Drug Device Combination Products: Distribution by Therapeutic Area
Figure 9.8 Large Volume Drug Device Combination Products: Distribution by Type of Dosage
Figure 9.9 Large Volume Drug Device Combination Products: Distribution by Storage Volume / Capacity (in mL)
Figure 9.10 Large Volume Drug Device Combination Products: Distribution by Usability
Figure 9.11 Large Volume Drug Device Combination Products: Distribution by Drug ompatibility
Figure 9.12 Large Volume Drug Device Combination Products: Distribution by Drug Container
Figure 9.13 Large Volume Drug Device Combination Products Developers: Distribution by Year of Establishment
Figure 9.14 Large Volume Drug Device Combination Products Developers: Distribution by Company Size
Figure 9.15 Large Volume Drug Device Combination Products: Distribution by Location of Headquarters
Figure 9.16 Most Active Players: Distribution by Number of Products Manufactured
Figure 9.17 Approved Prefilled Syringes Combination Products: Distribution by Type of Drug Molecule
Figure 9.18 Approved Prefilled Syringes Combination Products: Distribution by Approval Year
Figure 9.19 Approved Prefilled Syringes Combination Products: Distribution by Geography
Figure 9.20 Approved Prefilled Syringes Combination Products: Distribution by Route of Administration
Figure 9.21 Approved Prefilled Syringes Combination Products: Distribution by Therapeutic Area
Figure 9.22 Approved Prefilled Syringes Combination Products: Distribution by Other Dosage Forms
Figure 9.23 Clinical Stage Prefilled Syringes Combination Products: Distribution by Type of Drug Molecule
Figure 9.24 Clinical Stage Prefilled Syringes Combination Products: Distribution by Phase of Development
Figure 9.25 Clinical Stage Prefilled Syringes Combination Products: Distribution by Route of Administration
Figure 9.26 Clinical Stage Prefilled Syringes Combination Products: Distribution by Therapeutic Area
Figure 9.27 Prefilled Syringes Combination Product Developers: Distribution by Year of Establishment
Figure 9.28 Prefilled Syringes Combination Product Developers: Distribution by Company Size
Figure 9.29 Prefilled Syringes Combination Product Developers: Distribution by Location of Headquarters
Figure 10.1 Outsourcing: Go / No-Go Framework
Figure 10.2 Outsourcing: Go / No-Go Framework for Prefilled Syringes CombinationProduct Developers
Figure 10.3 Prefilled Syringes Combination Products Developers: Benchmarking of Very Small / Small Companies
Figure 10.4 Prefilled Syringes Combination Products Developers: Benchmarking of Mid-sized Companies
Figure 10.5 Prefilled Syringes Combination Products Developers: Benchmarking of Large Companies
Figure 11.1 Global Combination Products Service Providers Market, 2022-2035 (USD Million)
Figure 11.2 Global Combination Products Service Providers Market: Distribution by Type of Device, 2022 and 2035 (USD Million)
Figure 11.3 Combination Products Service Providers Market for Large Volume Wearable Injectors, 2022-2035 (USD Million)
Figure 11.4 Combination Products Service Providers Market for Autoinjector, 2022-2035 (USD Million)
Figure 11.5 Combination Products Service Providers Market for Prefilled Syringes, 2022-2035 (USD Million)
Figure 11.6 Combination Products Service Providers Market for Other Types of Combination Products, 2022-2035 (USD Million)
Figure 11.7 Global Combination Products Service Providers Market: Distribution by Service Focus Area, 2022 and 2035 (USD Million)
Figure 11.8 Combination Products Service Providers Market for Particle Testing, 2022-2035 (USD Million)
Figure 11.9 Combination Products Service Providers Market for Performance Testing2022-2035 (USD Million)
Figure 11.10 Combination Products Service Providers Market for Product Development, 2022-2035 (USD Million)
Figure 11.11 Global Combination Products Service Providers Market: Distribution by Company Size, 2022 and 2035 (USD Million)
Figure 11.12 Combination Products Service Providers Market for Very Small Companies, 2022-2035 (USD Million)
Figure 11.13 Combination Products Service Providers Market for Small Companies, 2022-2035 (USD Million)
Figure 11.14 Combination Products Service Providers Market for Mid-sizedCompanies 2022-2035 (USD Million)
Figure 11.15 Combination Products Service Providers Market for Large Companies, 2022-2035 (USD Million)
Figure 11.16 Combination Products Service Providers Market for Very LargeCompanies 2022-2035 (USD Million)
Figure 11.17 Global Combination Products Service Providers Market: Distribution by Region, 2022 and 2035 (USD Million)
Figure 11.18 Combination Products Service Providers Market in North America, 2022-2035 (USD Million)
Figure 11.19 Combination Products Service Providers Market in Europe, 2022-2035 (USD Million)
Figure 11.20 Combination Products Service Providers Market in Asia, 2022-2035 (USD Million)
Figure 11.21 Combination Products Service Providers Market in Rest of the World, 2022-2035 (USD Million)
Figure 12.1 Conclusion: Combination Products Service Providers Market Landscape
Figure 12.2 Conclusion: Company Competitiveness Analysis
Figure 12.3 Conclusion: Recent Expansions
Figure 12.4 Conclusion: Combination Products Case Study on Large Volume Wearable Injectors and Prefilled Syringes
Figure 12.5 Conclusion: Likely Partner Analysis
Figure 12.6 Conclusion: Outsourcing Go / No-Go Framework
Figure 12.7 Conclusion: Market Forecast

List Of Tables

Table 4.1 Combination Products Service Providers: Information on Year of Establishment, Company Size and Location of Headquarters
Table 4.2 Combination Products Service Providers: Information on Type of Combination Product
Table 4.3 Combination Products Service Providers: Information on Type of Device
Table 4.4 Combination Products Service Providers: Information on Service Focus Area(s)
Table 4.5 Combination Products Service Providers: Information on Type of Service(s) Offered
Table 4.6 Combination Products Service Providers: Information on Location of Facility(s)
Table 6.1 Combination Products Service Providers: List of Companies Profiled
Table 6.2 EKG LABS: Company Overview
Table 6.3 Eurofins Medical Device Testing: Company Overview
Table 6.4 Eurofins Medical Device Testing: Recent Developments and Future Outlook
Table 6.5 Exponent: Company Overview
Table 6.6 Exponent: Recent Developments and Future Outlook
Table 6.7 Kymanox: Company Overview
Table 6.8 Kymanox: Recent Developments and Future Outlook
Table 6.9 Medical Engineering Technologies: Company Overview
Table 6.10 Medical Engineering Technologies: Recent Developments and Future Outlook
Table 6.11 Pace Analytical Services: Company Overview
Table 6.12 Pace Analytical Services: Recent Developments and Future Outlook
Table 6.13 Suttons Creek: Company Overview
Table 6.14 Suttons Creek: Recent Developments and Future Outlook
Table 6.15 West Pharmaceutical Services: Company Overview
Table 6.16 West Pharmaceutical Services: Recent Developments and Future Outlook
Table 7.1 Combination Products Service Providers: List of Expansions, 2017-2022
Table 8.1 Large Volume Drug Device Combinations: Information on Phase of Development and Device Features
Table 8.2 Large Volume Drug Device Combinations: Information on Drug Administration Related Parameters
Table 8.3 Large Volume Wearable Injectors for Drug Device Combinations: Information on Developers
Table 8.4 Prefilled Syringes Combination Products: List of Approved Drugs, 2013-2021
Table 8.5 Prefilled Syringes Combination Products: Information on Approval Year, 2013-2021
Table 8.6 Prefilled Syringes Combination Products: Information on Target Indication(s) and Dosage Strength
Table 8.7 Prefilled Syringes Combination Products: List of Other Drug Delivery Solutions, 2013-2021
Table 8.8 Prefilled Syringes Combination Products: List of Clinical Stage Drugs
Table 8.9 Prefilled Syringes Combination Products: List of Developers
Table 9.1 Most Likely Partners
Table 9.2 Likely Partners
Table 9.3 Least Likely Partners
Table 14.1 Combination Products Service Providers: Cumulative Distribution by Year of Establishment
Table 14.2 Combination Products Service Providers: Distribution by Company Size
Table 14.3 Combination Products Service Providers: Distribution by Location of Headquarters
Table 14.4 Combination Products Service Providers: Distribution by Company Size and Location of Headquarters
Table 14.5 Combination Products Service Providers: Distribution by Type of Combination Product
Table 14.6 Combination Products Service Providers: Distribution by Company Size and Type of Combination Product
Table 14.7 Combination Products Service Providers: Distribution by Type of Device
Table 14.8 Combination Product Service Providers: Distribution by Service Focus Area(s)
Table 14.9 Combination Product Service Providers: Distribution by Type of Service(s) Offered
Table 14.10 Combination Product Service Providers: Distribution by Location of Facility (Region-wise)
Table 14.11 Combination Product Service Providers: Distribution by Location of Facility (Country-wise)
Table 14.12 Leading Combination Product Service Providers: Distribution by Number of Key Service(s) Offered
Table 14.13 4D Bubble Analysis: Distribution by Company Size, Company Headquarters (Region), Number of Service Focus Area(s) and Number of
Table 14.14 Mekko Representation: Distribution by Company Size and Service Focus Area(s)
Table 14.15 Recent Expansions: Cumulative Year-wise Trend, 2017-2022
Table 14.16 Recent Expansions: Distribution by Type of Expansion
Table 14.17 Recent Expansions: Distribution by Year of Expansion and Type of Expansion
Table 14.18 Recent Expansions: Distribution by Location of Expanded Facility
Table 14.19 Recent Expansions: Distribution by Type of Expansion and Location of Expanded Facility
Table 14.20 Recent Expansions: Distribution by Type of Expansion (Country-wise)
Table 14.21 Recent Expansions: Distribution by Location of Expanded Facility and Type of Expansion (Country-wise)
Table 14.22 Most Active Players: Distribution by Number of Recent Expansions
Table 14.23 Large Volume Drug Device Combinations: Distribution by Phase of Development
Table 14.24 Large Volume Drug Device Combinations: Distribution by Type of Device
Table 14.25 Large Volume Drug Device Combinations: Distribution by Mechanism of Action
Table 14.26 Large Volume Drug Device Combinations: Distribution by Type of Technology Used
Table 14.27 Large Volume Drug Device Combinations: Distribution by Route of Administration
Table 14.28 Large Volume Drug Device Combinations: Distribution by Method of Administration
Table 14.29 Large Volume Drug Device Combinations: Distribution by Therapeutic Area
Table 14.30 Large Volume Drug Device Combinations: Distribution by Type of Dosage
Table 14.31 Large Volume Drug Device Combinations: Distribution by Storage Volume / Capacity (in mL)
Table 14.32 Large Volume Drug Device Combinations: Distribution by Usability
Table 14.33 Large Volume Drug Device Combinations: Distribution by Drug Compatibility
Table 14.34 Large Volume Drug Device Combinations: Distribution by Drug Container
Table 14.35 Large Volume Wearable Injectors for Drug Device Combinations: Distribution of Developers by Year of Establishment
Table 14.36 Large Volume Wearable Injectors for Drug Device Combinations: Distribution of Developers by Company Size
Table 14.37 Large Volume Wearable Injectors for Drug Device Combinations: Distribution of Developers by Location of Headquarters
Table 14.38 Leading Players: Distribution by Number of Products
Table 14.39 Approved Prefilled Syringes Combination Products: Distribution by Type of Drug Molecule
Table 14.40 Approved Prefilled Syringes Combination Products: Distribution by Approval Year
Table 14.41 Approved Prefilled Syringe Combination Products: Distribution by Geography
Table 14.42 Approved Prefilled Syringe Combination Products: Distribution by Route of Administration
Table 14.43 Approved Prefilled Syringe Combination Products: Distribution by Therapeutic Area
Table 14.44 Approved Prefilled Syringe Combination Products: Distribution by Other Dosage Forms
Table 14.45 Clinical Stage Prefilled Syringes Combination Products: Distribution by Type of Drug Molecule
Table 14.46 Clinical Stage Prefilled Syringes Combination Products: Distribution by Phase of Development
Table 14.47 Clinical Stage Prefilled Syringes Combination Products: Distribution by Route of Administration
Table 14.48 Clinical Stage Prefilled Syringes Combination Products: Distribution by Therapeutic Area
Table 14.49 Prefilled Syringe Combination Product Developers: Distribution by Year of Establishment
Table 14.50 Prefilled Syringe Combination Product Developers: Distribution by Company Size
Table 14.51 Prefilled Syringe Combination Product Developers: Distribution by Location of Headquarters
Table 14.52 Global Combination Products Service Providers Market, 2022-2035 (USD Million), Conservative, Base and Optimistic Scenarios
Table 14.53 Global Combination Products Service Providers Market: Distribution by Type of Device, 2022 and 2035
Table 14.54 Combination Products Service Providers Market for Large Volume Wearable Injectors, 2022-2035 (USD Million), Conservative, Base and Optimistic Scenarios
Table 14.55 Combination Products Service Providers Market for Autoinjectors, 2022-2035 (USD Million), Conservative, Base and Optimistic Scenarios
Table 14.56 Combination Products Service Providers Market for Prefilled Syringes, 2022-2035 (USD Million), Conservative, Base and Optimistic Scenarios
Table 14.57 Combination Products Service Providers Market for Other Types of Combination Products, 2022-2035 (USD Million), Conservative, Base and Optimistic Scenarios
Table 14.58 Global Combination Products Service Providers Market: Distribution by Service Focus Area, 2022 and 2035
Table 14.59 Combination Products Service Providers Market for Particle Testing, 2022-2035 (USD Million), Conservative, Base and Optimistic Scenarios
Table 14.60 Combination Products Service Providers Market for Performance Testing2022-2035 (USD Million), Conservative, Base and Optimistic Scenarios
Table 14.61 Combination Products Service Providers Market for Product Development, 2022-2035 (USD Million), Conservative, Base and
Table 14.62 Global Combination Products Service Providers Market: Distribution by Company Size, 2022 and 2035
Table 14.63 Combination Products Service Providers Market for Very Small Companies, 2022-2035 (USD Million), Conservative, Base and
Table 14.64 Combination Products Service Providers Market for Small Companies, 2022-2035 (USD Million), Conservative, Base and Optimistic Scenarios
Table 14.65 Combination Products Service Providers Market for Mid-sizedCompanies 2022-2035 (USD Million), Conservative, Base and Optimistic
Table 14.66 Combination Products Service Providers Market for Large Companies, 2022-2035 (USD Million), Conservative, Base and Optimistic Scenarios
Table 14.67 Combination Products Service Providers Market for Very LargeCompanies 2022-2035 (USD Million), Conservative, Base and Optimistic
Table 14.68 Global Combination Products Service Providers Market: Distribution by Region, 2022 and 2035
Table 14.69 Combination Products Service Providers Market in North America, 2022-2035 (USD Million), Conservative, Base and Optimistic Scenarios
Table 14.70 Combination Products Service Providers Market in Europe, 2022-2035 (USD Million), Conservative, Base and Optimistic Scenarios
Table 14.71 Combination Products Service Providers Market in Asia, 2022-2035 (USD Million), Conservative, Base and Optimistic Scenarios
Table 14.72 Combination Products Service Providers Market in Rest of the World, 2022-2035 (USD Million), Conservative, Base and Optimistic Scenarios

List Of Companies

The following companies and organizations have been mentioned in the report:

1. Angiplast
2. 3M
3. Abbott Laboratories
4. AbbVie
5. Accord Healthcare
6. Adamis Pharmaceuticals 
7. Adimmune
8. Alder BioPharmaceuticals
9. Alkermes
10. Alvogen
11. Alvotech
12. Amgen
13. Amgen
14. Amphastar Pharmaceuticals
15. anteris medical
16. Apobiologix
17. Asarina Pharma
18. AstraZeneca
19. B.Braun
20. Basic Laboratory
21. BD
22. Bio-Concept Laboratories
23. Biogen
24. Bioinova
25. Boehringer Ingelheim
26. Bone Therapeutics
27. Braeburn Pharmaceuticals
28. Bristol-Myers Squibb
29. Camurus
30. Celltrion
31. Centrexion Therapeutics
32. Chugai Pharmaceuticals
33. Coherus BioSciences
34. Con-Test Analytical Laboratory (Acquired by Pace Analytical® Services)
35. Cumberland Pharmaceuticals
36. Cycle Pharmaceuticals
37. DDL
38. Department of Defense 
39. Drug Delivery Experts
40. Dynavax Technologies
41. EdgeOne Medical
42. EKG Labs
43. Element Materials Technology
44. Eli Lilly
45. EMD Serono
46. Emerson Resources (Acquired by Pace Analytical® Services)
47. Eurofins Medical Device Testing
48. EVER Pharma
49. Exemplar Compliance
50. Exponent
51. Foresee Pharmaceuticals
52. Fresenius Kabi
53. Fujifilm
54. GC Pharma
55. GENERON
56. Genetech
57. Genmab
58. Gerresheimer
59. Gilero
60. GlaxoSmithKline
61. Glenmark Pharmaceuticals
62. Hanmi Pharmaceutical
63. Heron Therapeutics
64. Hetero Healthcare
65. Il-Yang Pharm
66. Insulet
67. Ipsen
68. IWA Consulting
69. Janssen
70. Kiniksa Pharmaceuticals
71. Kymanox
72. Kyowa Kirin
73. Salvat Laboratories 
74. LEO Pharma
75. Lubrizol Life Science
76. Lundbeck
77. Medicago
78. Medical Engineering Technologies
79. MEDIcept
80. Merck
81. Milfra (Acquired by Nemera)
82. Mithra Pharmaceuticals
83. Mitsubishi Tanabe Pharma
84. Momenta Pharmaceuticals
85. MorphoSys
86. NAMSA
87. Nelson Labs
88. NEUMA 
89. NeuroDerm
90. Nexus Pharmaceuticals
91. Novartis
92. Novocol Pharmaceuticals
93. NubGenix
94. Oncobiologics
95. Otsuka Pharmaceutical
96. Pace Analytical® Services
97. Pfizer
98. PharmaEssentia 
99. Phillips-Medisize
100. Piramal Enterprises
101. PTC Therapeutics
102. Regeneron
103. RHEACELL
104. Roche
105. Samsung Bioepis
106. Sandoz
107. Sanofi
108. Sanofi Pasteur
109. scPharmaceuticals
110. Seqirus
111. Shire
112. Special Pathogens Laboratory
113. Sun Pharma
114. Surpass
115. Suttons Creek
116. Swedish Orphan Biovitrum
117. Takeda Pharmaceuticals
118. Teva Pharmaceutical
119. UCB Biopharma
120. United Therapeutics
121. US Department of Health and Human Services 
122. Valeant Pharmaceuticals
123. Velesco Pharmaceutical Services
124. Vitaeris
125. West Pharmaceutical Services
126. WestView Capital Partners
127. Wickham Micro
128. WuXi AppTec
129. Xeris Pharmaceuticals
130. YL Biologics
131. Zealand Pharma
132. ZebraSci
133. Zhejiang Huahai Pharmaceutical